Human Papilloma Virus Distribution Across the African Diaspora

Patricia Jeudin, MD1,2; Tamrat Abebe, PhD2,3; Raleigh Butler, MD2,4; Desiree Hooi, MD, PhD2,5; Angela Watt, PhD2,6; Callinice D. Capo-chichi, PhD2,7; Sophia George, PhD1,2; Camille Regin, PhD, MPH2,8; Normal McFarlaneAnderson, PhD2,6; and Matthew Schlumbrecht, MD, MPH1,2

abstract

PURPOSE Understanding the distribution of human papilloma virus (HPV) subtypes in limited-resource settings is imperative for cancer prevention strategies in these regions. The objective of our study is to compare the prevalence of cervical HPV genotypes in women across the African diaspora.

METHODS This study was approved by the African Caribbean Consortium (AC3). Six member institutions (Benin, Ethiopia, The Bahamas, Tobago, Curacao, and Jamaica) provided independently collected HPV data. Prevalence comparisons across for each nation were performed followed by an assessment of anticipated 9-valent vaccine coverage. Chi-square or Fisher’s exact tests were used with significance at $P < .05$.

RESULTS One thousand three hundred fifty high-risk (HR) and 584 low-risk (LR) HPV subtypes were identified in the entire cohort. The most common HR HPV subtype was HPV 16 (17.9%) of infections. The distribution of HR and LR subtypes varied by country. The proportion of HR-HPV subtypes covered by the current 9-valent vaccine was lower in African countries compared with the Caribbean countries (47.9% vs 67.9%; $P = .01$). No significant difference was seen for LR subtypes (8.1% African continent vs 5.2% Caribbean; $P = .20$). Marked variation in the proportion of infections covered by the 9-valent vaccine persisted in individual countries.

CONCLUSION Significant variations in HPV prevalence were identified among African and Afro-Caribbean women. A large number of women in these regions are potentially uncovered by current vaccination formulation, particularly low-risk HPV infections.

JCO Global Oncol 7:1206-1208. © 2021 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

INTRODUCTION More than 80% of new cervical cancer diagnoses and deaths occur in low- and middle-income countries. The greatest burden is seen primarily in African countries as well as the Caribbean and Latin America. Persistent infection with high-risk human papilloma virus (HR-HPV) leads to cancer, whereas infection with low-risk HPV (LR-HPV) causes genital warts. Although HPV 16/18 causes 70% of cervical cancers in the United States, the role of other genotypes is warranted in more diverse populations. Baseline estimates of HPV genotypes have shown HPV 62 to be the most prevalent genotype in women age 14-59 years. Furthermore, HPV genotype prevalence may vary across regions. A nonvalent HPV vaccine has been introduced as a means to decrease the burden of HPV-related cancers, but only covers certain genotypes. The objective of this study was to identify the prevalence of HR and LR HPV genotypes in African and Caribbean countries.

METHODS The study was approved and conducted by the African Caribbean Cancer Consortium (AC3). A collaborative cross-sectional analysis was performed across affiliated institutions in Africa (Ethiopia and Benin) and the Caribbean (The Bahamas, Curacao, Jamaica, and Tobago). Cervical samples were collected from women undergoing screening assessments at each institution independently and analyzed. HPV DNA testing was performed on all collected samples, with identified HR-HPV and LR-HPV genotypes reported in their respective cohorts. HPV prevalence was compared across nations. Chi-square and Fisher’s exact tests were used with a significance set at $P < .05$.

RESULTS HPV genotypes were recorded in 1,350 women across all sites. HIV status was not available for all the patients in this study. Table 1 lists the most common HPV genotypes by country. Significant variation exists in the prevalence of HR-HPV and LR-HPV genotypes across the African diaspora. HR-HPV 16 was the most common HR genotype in the entire cohort, but overall comprised < 20% of infections. On an individual country level, this genotype was most prevalent in only
two countries, Curacao and Ethiopia. The remaining countries showed a higher prevalence of other HR-HPV genotypes, including HPV 18, 45, 52, and 66. HPV 62 was the most common LR-HPV genotype. In only one country, Curacao, was LR-HPV 6 the most common LR-HPV genotype.

Table 2 demonstrates the proportions of HPV infections covered by nonvalent vaccine across the cohorts. The proportion of genotypes covered by nonvalent vaccine overall was lower in African countries compared with Caribbean countries (47.9% vs 67.9%; \( P < .01 \)). When evaluated on a country level, there was marked variation in the proportions of genotypes covered by the vaccine, with very low coverage of LR-HPV genotypes in the majority of locations.

**DISCUSSION**

In conclusion, the findings of this study demonstrate significant variations in HR-HPV and LR-HPV genotypes present in cervical samples among West and East African and Afro-Caribbean women living in their native countries. Women in The Bahamas, Jamaica, and Tobago have higher rates of non-16/18 HR-HPV infections. Furthermore, among the women with abnormal cervical pap smears, the most common HPV subtypes were non-HPV 16/18 HR subtypes. Previous studies in Tobago demonstrated that the most common HR-HPV subtype in cervical samples was HPV 45.\(^6\) This suggests that HPV genotypes may vary at different periods within the same population. Current vaccine formulations do not cover the majority of LR-HPV genotypes in the countries studied, and fewer than two thirds of women would be protected against HR-HPV genotypes. These findings are important as efforts to decrease the cervical cancer incidence globally focus primarily on vaccination and screening. Although the lack of access to care plays a major role in cervical cancer incidence and mortality, other etiologies continue to warrant investigation. Understanding the nuances of unique subpopulations, especially women with the highest burden of disease, is crucial to eliminate global disparities in disease incidence and outcomes. Current screening and management recommendations risk stratify Pap results on the basis of the presence of HPV 16/18.\(^7\) The findings of this study suggest that further research and consideration of other HPV genotypes are necessary for the development of screening programs across the globe and may help influence strategies for HPV vaccine optimization and/or personalization in populations around the world.

**CONTEXT**

**Key Objective**

Does the current human papilloma virus (HPV) vaccine formulation provide protection against high-risk (HR) and low-risk (LR) HPV infections in African and Afro-Caribbean populations?

**Knowledge Generated**

HPV 16 remains the most-common HR infection in this cohort, although the prevalence of specific HR and LR HPV subtypes varies by country. Because of the differences in HR-HPV and LR-HPV infections that exist among African and Afro-Caribbean populations, a large number of women may remain uncovered by the 9-valent vaccine.

**Relevance**

In low-resource settings, screening for cervical cancer is limited. The HPV vaccine has been proven as method to both prevent cancer and reduce the development of high-grade dysplastic lesions from HPV infection. In regions with a high prevalence of cervical cancer, it is imperative that prevention methods are applicable and beneficial to the population.

---

**TABLE 1. Most Common HPV Subtypes, by Country**

| Country      | HR Genotype (percent of HR infections) | LR Genotype (percent of LR infections) |
|--------------|---------------------------------------|----------------------------------------|
| The Bahamas  | HPV 18 (15.8%)                        | HPV 62 (15%)                           |
| Benin        | HPV 66 (12.6%)                        | HPV 43/44 (64.6%)                      |
| Curacao      | HPV 16 (42.1%)                        | HPV 6 (37.5%)                          |
| Ethiopia     | HPV 16 (21.8%)                        | HPV 53 (30.8%)                         |
| Jamaica      | HPV 45 (15.1%)                        | HPV 62 (13.7%)                         |
| Tobago (2006)| HPV 52 (15%)                          | HPV 54 (15.8%)                         |

Abbreviations: HPV, human papilloma virus; HR, high-risk; LR, low-risk.

**TABLE 2. Proportion of Human Papilloma Virus Infections Covered by Current 9-Valent Vaccine, by Country**

| Country      | High-Risk (%) | Low-Risk (%) |
|--------------|---------------|--------------|
| The Bahamas  | 60.5          | 6.8          |
| Benin        | 44.2          | 4.7          |
| Curacao      | 84.2          | 37.5         |
| Ethiopia     | 49.5          | 9.4          |
| Jamaica      | 65.2          | 4.2          |
| Tobago       | 53.3          | 0            |

\( P \) value for intercountry proportional differences: < .01 < .01
AFFILIATIONS
1Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, MI
2African Caribbean Cancer Consortium, Philadelphia, PA
3Department of Microbiology, Immunology & Parasitology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia
4Department of Obstetrics & Gynecology, University of the West Indies, Nassau, Bahamas
5Department of Pathology, VU University Medical Center, Amsterdam, Netherlands Antilles
6Department of Basic Medical Sciences, University of West Indies, Mona, Jamaica
7Division of Molecular Biomarkers in Cancer and Nutrition, University of Abomey-Calavi, Cotonou, Benin
8Cancer Prevention and Control Program at Fox Chase Cancer Center-Temple Health, Philadelphia, PA

CORRESPONDING AUTHOR
Patricia Jeudin, MD, Sylvester Comprehensive Cancer Center, 1121 NW 14th St, Suite 345D, Miami, FL 33136; e-mail: pjeudin@med.miami.edu.

DISCLAIMER
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

SUPPORT
Supported by the National Cancer Institute of the National Institutes of Health under Award No. P30CA240139.

AUTHOR CONTRIBUTIONS
Conception and design: Tamrat Abebe, Callinice D. Capo-chichi, Sophia George, Camille Ragin, Normal McFarlane Anderson, Matthew Schlumbrecht
Financial support: Tamrat Abebe
Administrative support: Tamrat Abebe
Provision of study materials or patients: Tamrat Abebe, Raleigh Butler, Desiree Hooi, Callinice D. Capo-chichi, Normal McFarlane Anderson
Collection and assembly of data: Tamrat Abebe, Raleigh Butler, Desiree Hooi, Angela Watt, Camille Ragin, Normal McFarlane Anderson, Matthew Schlumbrecht
Data analysis and interpretation: Patricia Jeudin, Tamrat Abebe, Sophia George, Normal McFarlane Anderson, Matthew Schlumbrecht
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Matthew Schlumbrecht
Consulting or Advisory Role: Tesaro

No other potential conflicts of interest were reported.

REFERENCES
1. Small W Jr, Bacon MA, Bajaj A, et al: Cervical cancer: A global health crisis. Cancer 123:2404-2412, 2017
2. Pilleron S, Cabasag CJ, Ferlay J, et al: Cervical cancer burden in Latin America and the Caribbean: Where are we? Int J Cancer 147:1638-1648, 2020
3. Jedy-Agba E, Joko WY, Liu B, et al: Trends in cervical cancer incidence in sub-Saharan Africa. Br J Cancer 123:148-154, 2020
4. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018
5. Dunne EF, Unger ER, Sternberg M, et al: Prevalence of HPV infection among females in the United States. JAMA 297:813-819, 2007
6. Ragin CCR, Wheeler VW, Wilson JB, et al: Distinct distribution of HPV types among cancer-free Afro-Caribbean women from Tobago. Biomarkers 12:510-522, 2007
7. Perkins RB, Guido RS, Castle PE, et al: 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 24:102-131, 2020